leadf
logo-loader
viewNoxopharm Ltd
(
ASX:NOX
)

Noxopharm secures key European patent allowance for Veyonda® anti-cancer drug candidate

The clinical-stage drug development company believes, if a patent is granted, it will support its ambition to make Veyonda a standard of care drug in combination with major cancer therapies.

Noxopharm Ltd - Noxopharm nabs European patent allowance for Veyonda®
Noxopharm is one step closer to securing a patent for its anti-cancer drug candidate.

Noxopharm Ltd (ASX:NOX) is trading higher after securing a crucial European patent allowance for its Veyonda® anti-cancer drug candidate.

Specifically, the European Patent Office has issued a formal Notice of Allowance of claims for patent application number 17778482.4, indicating an intention to move to the patent grant stage.

Overall, Noxopharm believes the patent allowance bodes well for related Veyonda patent applications in Europe and other important territories such as the US.

Veyonda is an immune-oncology drug that works with the body’s defence mechanisms to fight cancer cells.

It moderates and inhibits cancer cell signalling and complements existing therapies like radiation treatment and chemotherapy, enhancing the efficacy of these therapies.

Investors have also greeted the news with shares up as much as 8.4% to A$0.65.

"Very pleasing validation”

Noxopharm CEO Graham Kelly said: “This allowance is very pleasing validation of our strategy of building a strong IP position around Veyonda based on a series of inter-connected patents.

“The interconnection is between method of administration and clinical use and removes the reliance on the strength of any single patent.”

A granted patent also will help underpin our commercial aim of Veyonda becoming a standard of care drug in combination with other major forms of cancer therapy.”

A crucial patent

Once granted, Noxopharm’s new European patent will be tied to the therapeutic use of its idronoxil immune-oncology drug in a suppository dosage formulation, intended to provide a steady-state blood level of drug.

The patent will run through to April 2037, meaning Noxopharm’s Veyonda candidate has enforceable rights under patent protection for another 16 years.

It is also not limited to a particular cancer type, should cover the treatment of any cancer and can be administered to patients who have received or are receiving chemotherapy or radiotherapy.

Just weeks ago, Noxopharm announced it was preparing for a Phase Two Veyonda trial for its upcoming DARRT-2 study. 

Patients enrolled in the study will participate across Australia, the US, France and Hungary at around 15 trial sites.

Quick facts: Noxopharm Ltd

Follow
ASX:NOX

Price: 0.565 AUD

Market Cap: $162.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Noxopharm to expand NOXCOVID program following positive phase 1 results

Noxopharm Ltd (ASX:NOX)'s Graham Kelly tells Proactive they're planning to expand its NOXCOVID clinical program after receiving positive preliminary top-line data from its Phase 1 clinical trial for patients with coronavirus. The company's positioning Veyonda (idronoxil) as an anti-inflammatory...

on 24/8/21

2 min read